Pluri Inc Stock Forum

$SU Group Holdings (SUGP.US)$ $The OLB Group (OLB.US)$ $Pineapple Financial (PAPL.US)$ $Pluri Inc (PLUR.US)$ $Agrify (AGFY.US)$ $SemiLEDs (LEDS.US)$ $Advent Technologies (ADN.US)$ $Protagenic Therapeutics (PTIX.US)$ $Vertical Aerospace (EVTL.US)$ $Genprex (GNPX.US)$ $LogicMark (LGMK.US)$ $BTC Digital (BTCT.US)$
📊⚡️📊

$SRM Entertainment (SRM.US)$ $Pluri Inc (PLUR.US)$ $Vaccinex (VCNX.US)$ $Wang & Lee Group (WLGS.US)$ $Alliance Entertainment Holding (AENT.US)$ $Unusual Machines (UMAC.US)$ $BIO-key International (BKYI.US)$ $Genprex (GNPX.US)$ $Top Wealth Group Holding (TWG.US)$ $180 Life Sciences (ATNF.US)$ $Tenon Medical (TNON.US)$ $CareMax (CMAX.US)$ $Yoshiharu Global (YOSH.US)$ $1847 Holdings (EFSH.US)$
🎃⚡️🎃

$Pluri Inc (PLUR.US)$
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority
Pluri Inc. (PLUR) announces a collaboration with Bar-Ilan University's BIRAD, funded by the Israel Innovation Authority, to advance cancer immunotherapy using Placental Mucosal Associated Invariant T (MAIT) cells for solid tumors. The partnership combines Pluri's proprietary MAIT cell expansion platform with Prof. Cyrille Cohen's Siglec-b...

$Pluri Inc (PLUR.US)$ $
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) has signed a tech transfer and manufacturing agreement with Kadimastem (TASE: KDST) through its PluriCDMO™ division.
PluriCDMO™ will manufacture two cell therapy product candidates for Kadimastem: AstroRx® for ALS treatment and IsletRx for diabetes treatment.
This collaboration leverages Pluri's 47,000 square foot GMP cell production facility a...

$Pluri Inc (PLUR.US)$ Pluri Says US NIAID Will Provide Company With $1.4M From July 1, 2024 To June 30, 2025; NIAID Exercised Its Option For Year Two Of The Three-year $4.2M Contract It Entered Into With Pluri In July 2023
Benzinga· just
The company will manufacture the PLX-R18 cell therapy and to conduct both in vitro and in vivo studies to develop PLX-R18 as a potential novel treatment for hematopoietic complications of the acute radiation syndrome (H-ARS).

$Pluri Inc (PLUR.US)$ Benzinga· 2 mins ago
Pluri Collaborated With Wilk Technologies To Develop Human Breast Milk-derived Food Production On A Commercial Scale

$Pluri Inc (PLUR.US)$
NEWS
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
Pluri Inc. launched a novel immunotherapy platform for solid tumor cancer treatment utilizing placental MAIT cells, a unique type of immune cells with great potential. Pluri's proprietary technology overcomes challenges in expanding MAIT cells, offering advantages over conventional T cells. The global cancer immunotherapy market is projected to reach $275.11 ...

$Pluri Inc (PLUR.US)$ Pluri Inc: on April 15, Got Letter From Nasdaq That Co Has Regained Compliance With Nasdaq Listing Rule 5550(a)(2)

$Pluri Inc (PLUR.US)$ Pluri Introduces Groundbreaking Immune Cell Expansion Technology, Secures New US Patent
Benzinga· 1 min ago
Leading biotechnology company, Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today unveiled a novel method for expansion of immune cells using proprietary technology and announced it was granted a new U.S. patent titled, "System and Methods for Immune Cells Ex...